Merck has added 120,000 square feet of manufacturing capacity at its Rockingham County site to support its Gardasil HPV vaccines.

Dan Stanton, Managing editor

April 4, 2022

1 Min Read
Merck completes $1bn HPV vaccine expansion in Virginia
Image: Stock Photo Secrets n

Merck & Co. has added 120,000 square feet of manufacturing capacity at its Rockingham County site to support continued scale-up of its Gardasil HPV vaccines.

Human papillomavirus (HPV) vaccines Gardasil and Gardasil 9 pulled in $1.5 billion for Merck last year, and while the firm has predicted sales to double by 2030 as demand continues, this is reliant on having the manufacturing capacity in place.


Image: Stock Photo Secrets

With this in mind, it is good news today for Merck as it announces the completion of a $1 billion investment at its Elkton facility in Rockingham County, Virginia. The expansion, first announced in H1 2019, adds 120,000 square feet of manufacturing space to the 1.1 million square-foot site and adds 150 new jobs.

““Increasing supply of our HPV vaccines is a top priority, and over the last several years we have steadily increased our manufacturing capacity in response to growing global demand,” Jacks Lee, senior vice president, Merck Manufacturing said in a statement.

“Despite the pandemic, our teams have completed the building infrastructure expansion at our Elkton site ahead of schedule and we are excited to reach this important milestone.”

A second investment of $680 million in its Gardasil network was announced in H2 2019. The expansion comprises of $650 million to construct a facility at its Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, North Carolina and $30 million to expand a nearby packaging site in Wilson.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like